News and blog posts
22
Aug 2018
The report presents a summary of the reimbursement situation for creation of vascular access for long-term use in Europe. Report includes analysis for creation of AV fistula and placement of AV graft. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.
Read more
22
Aug 2018
The report presents a summary of the reimbursement situation for hernia repair. Report includes analysis for inguinal hernia, incisional hernia, umbilical hernia and femoral hernia. Use of synthetic and biological mesh devices is considered in the report. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.
Read more
22
Aug 2018
The report presents a summary of the reimbursement situation for bariatric surgery. Report includes analysis for placement of adjustable gastric band, sleeve gastrectomy, and gastric bypass. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.
Read more
22
Aug 2018
INAMI/RIZIV launched a call for projects via the application of negative pressure wound therapy in home nursing until August 31, 2018. Funding for a project depends on the number of treatment periods started, with a maximum of €1,000 per patient.
Read more
21
Aug 2018
A national ‘pause’ has been announced in the use of surgical mesh/tape to treat stress urinary incontinence and for urogynaecological prolapse where the mesh is inserted through the vaginal wall. This pause takes the form of a high vigilance restriction, and all cases should be postponed immediately if it is clinically safe to do so.
Read more
20
Aug 2018
The Danish National Board of Health has implemented funds for experimental cancer surgery for the period of 2017-2020. The deadline for the second round of applications lasts until September 5, 2018.
Read more
17
Aug 2018
In June 2018, Danish Health Authority published new codes for the Health Care Classification System, including two surgical, two medical procedure codes and three codes for MRI diagnostics. These codes are used to classify procedures in Danish DRG system.
Read more
16
Aug 2018
Hundreds of patients each year will benefit from fourteen new innovative treatments that will now be routinely available. These treatments include several devices and procedures: keraprosthesis for corneal blindness, left atrial appendage occlusion, selective dorsal rhizotomy and total pancreatectomy with islet transplantation for chronic pancreatitis.
Read more
15
Aug 2018
At the beginning of July 2018, the Swiss agency for therapeutic products, Swissmedic, has released an announcement about the upcoming changes about upcoming changes relating to the issuing of Export Certificates (FSC) and Manufacturing Certificates (MC).
Read more
14
Aug 2018
On 6th of July, 2018, the European network for health technology assessment, EUnetHTA, has opened the public consultation on ‘Horizon Scanning, Topic Identification, Selection and Prioritisation for European Cooperation on HTA – Draft recommendations.’
Read more
13
Aug 2018
Six new DRGs have been added for 2019, including proton therapy, insertion of functional implants in the urinary tract or male genitals and replacement of processor in cochleart implant.
Read more
10
Aug 2018
An article “An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany” was published in the BMC Cardiovascular Disorders. The study concluded that Baroreflex activation therapy (BAT) using the Barostim neo™ device (CVRx Inc., Minneapolis, MN, USA) compared with optimized medical management in patients with advanced chronic heart failure (NYHA class III) who were not eligible for treatment with cardiac resynchronization therapy, can be cost-effective from a statutory health insurance perspective in Germany over a lifetime horizon. The ICER was €27,951/QALY (95% CI €21,357–82,970).
Read more